- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01821547
New Methods to Measure the Immune Response to Hepatitis B Vaccine
Hepatitis B Immunisation: A Two-part Study Investigating Antigen Specific B Cell Receptors
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
Oxfordshire
-
Oxford, Oxfordshire, Vereinigtes Königreich, OX3 7LE
- Centre for Clinical Vaccinology & Tropical Medicine (CCVTM)
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
All participants for both parts 1 and 2 must meet the following conditions in order to be enrolled:
- Participant is willing and able to give informed consent for participation in the study
- Healthy Male or Female, aged 18 - 60 years
- No allergies to the vaccine or its excipients
Participants enrolling in Part 1 must also meet the following conditions:
- Participant has previously received a primary immunisation course of HepB vaccine (3 primary doses). The 4th booster dose recommended after 12 months is not a requirement. There are a variety of possible recommended schedules, and any may have been used as long as the final vaccine (or booster vaccine) was given at least 12 months prior to the participant enrolling in the study.
- Participant is willing to allow their General Practitioner to be notified, if appropriate, of participation in the study
Participants enrolling in Part 2 must also meet the following conditions Participant receiving HBvaxPro® (the usual vaccine given within the Occupational Health Department).
Exclusion Criteria:
The participant may not enter either study if ANY of the following apply:
Have any known or suspected impairment or alteration of immune function, resulting from, for example:
- Congenital or acquired immunodeficiency (including IgA deficiency)
- Human Immunodeficiency Virus infection or symptoms/signs suggestive of an HIV-associated condition
- Autoimmune disease
- Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 12 months or long-term systemic corticosteroid therapy.
- Chronic illness that could interfere with immunological function or donation of the required volumes of blood (e.g. cardiac or renal disease, diabetes, or auto-immune disorders).
- Receipt of a HepB booster vaccine within the past 12 months.
- Prior history of anaphylactic reaction to a previous dose of a Hepatitis B containing vaccine or known hypersensitivity to any vaccine component;
- Receipt of blood, blood products, or plasma derivatives within the past 3 months.
- Total blood donation greater than 50 ml within the past 3 months.
- Thrombocytopenia or any bleeding disorder.
- Pregnancy as confirmed by a positive pregnancy test, or currently breastfeeding.
- Receipt of a live vaccine within 4 weeks prior to vaccination or a killed vaccine within 7 days prior to vaccination.
- Plan to receive any vaccine other than the study vaccine within 4 weeks following vaccination.
- Enrolled in another study, which, in the opinion of the investigator, could compromise the integrity of either study being conducted.
- A member of staff on the delegation log
- According to the TOPS database, have recently taken part in a significant number of other studies, which, in the opinion of the investigator, warrant exclusion from further studies.
- Participant is a known non-responder to the HepB vaccine
- Have any condition, which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
- Unable to understand English, or what will be required from them during the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Part 2- To assess B cell VH/L gene segment usage by HepB specific B cells during and following administration of a three dose course of HepB vaccine given at 0,1, 2 or 0, 1, 6 months.
Zeitfenster: 0 and 7 days after the second immunisation, and 0, 7 and 40 days after the third immunisation
|
HepB specific cells will be isolated using magnetic-activated cell sorting, and fluorescence-activated cell sorting.
VH/L gene segments will be amplified by PCR, and DNA prepared for sequencing.
Bioinformatic approaches will then be used to create frequency tables of the different V, D and J exons that comprise these gene segments.
|
0 and 7 days after the second immunisation, and 0, 7 and 40 days after the third immunisation
|
Part 1- To validate B cell assays and assess the kinetics of HepB specific B cell subsets following administration of a booster dose of HepB vaccine given to previously immunised healthy adults.
Zeitfenster: 0, 7, 14, 21 and 28 days after immunisation
|
HepB specific B cell subsets will be identified using both ELISPOT and flow cytometry.
|
0, 7, 14, 21 and 28 days after immunisation
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Part 1 • To measure HepB surface antigen-specific antibody concentration following administration of a booster dose of HepB vaccine given to previously immunised healthy adults
Zeitfenster: 0 and 28 days after immunisation
|
Antibody concentrations will be determined from blood plasma using an ELISA
|
0 and 28 days after immunisation
|
Part 1 • To assess B-cell receptor VH/L gene sequences used in HepB specific and non-antigen specific B-cells prior to and following administration of a booster dose of HepB vaccine given to previously immunised healthy adults
Zeitfenster: 0, 7, 14, 21 and 28 days after immunisation
|
VH/L gene segments will be amplified by PCR, and DNA prepared for sequencing.
Bioinformatic approaches will then be used to create frequency tables of the different V, D and J exons that comprise these gene segments.
|
0, 7, 14, 21 and 28 days after immunisation
|
Part 1 • Comparison of B cell receptor VH/L gene segment usage as determined by two different next-generation sequencing methods (RNA-sequencing and 454).
Zeitfenster: 0, 7, 14, 21 and 28 days after immunisation, as required
|
Different sequencing protocols introduce different types of error and bias into the resulting sequence datasets.
VH/L gene segments will sequenced using two different techniques.
Bioinformatic approaches and descriptive analysis will then be used to compare the effects of the two different protocols.
Frequency tables of the different V, D and J exons that comprise these gene segments will be generated, for comparison.
|
0, 7, 14, 21 and 28 days after immunisation, as required
|
Part 1 • Collection of mRNA for subsequent gene expression analysis
Zeitfenster: 0, 7, 14, 21 and 28 days after immunisation
|
0, 7, 14, 21 and 28 days after immunisation
|
|
Part 2 • To measure HepB specific plasma and memory B cell frequencies during and following administration of a three dose course of HepB vaccine given at 0, 1, 2 or 0, 1, 6 months.
Zeitfenster: 0 and 7 days after the second immunisation, and 0, 7 and 40 days after the third immunisation
|
HepB specific B cell subsets will be identified using both ELISPOT and flow cytometry.
|
0 and 7 days after the second immunisation, and 0, 7 and 40 days after the third immunisation
|
Part 2 • To measure HepB surface antigen-specific antibody concentration during and following administration of a three dose course of HepB vaccine given at 0,1, 2 or 0, 1, 6 months.
Zeitfenster: 0 days after the second immunisation, and 0 and 40 days after the third immunisation
|
Antibody concentrations will be determined from blood plasma using an ELISA
|
0 days after the second immunisation, and 0 and 40 days after the third immunisation
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Dominic Kelly, Oxford Vaccine Group
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Leberkrankheiten
- Hepatitis, viral, menschlich
- Hepadnaviridae-Infektionen
- DNA-Virusinfektionen
- Enterovirus-Infektionen
- Picornaviridae-Infektionen
- Hepatitis B
- Hepatitis
- Hepatitis A
Andere Studien-ID-Nummern
- OVG 2012/09
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Hepatitis B
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi Hospital... und andere MitarbeiterRekrutierungPatienten mit chronischer Hepatitis b stellen nach Absetzen des Nukleosidanalogs auf tAf um (CHANGE)Chronische Hepatitis b | Hepatitis-B-ReaktivierungTaiwan
-
Mahidol UniversityUnbekanntChronische Hepatitis B, HBsAg, Hepatitis-B-ImpfstoffThailand
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNoch keine Rekrutierung
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnbekanntChronische Hepatitis b
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRekrutierungChronische Hepatitis b | Zirrhose durch Hepatitis BChina
-
Tongji HospitalGilead SciencesRekrutierung
-
Jiangsu HengRui Medicine Co., Ltd.Unbekannt
-
Changhai HospitalAbgeschlossenChronische Hepatitis bChina
-
Nanfang Hospital of Southern Medical UniversityRekrutierung
-
IlDong Pharmaceutical Co LtdRekrutierungChronische Hepatitis bKorea, Republik von
Klinische Studien zur Hepatitis B vaccine
-
Shaare Zedek Medical CenterUnbekannt
-
PT Bio FarmaRS Umum Pusat Sanglah, DenpasarNoch keine RekrutierungImpfstoff-Nebenwirkung | Impfstoffreaktion
-
Jiangsu Province Centers for Disease Control and...AbgeschlossenHepadnaviridae-Infektionen | DNA-Virusinfektionen | ViruskrankheitChina
-
PT Bio FarmaAbgeschlossen
-
University of California, DavisAbgeschlossen
-
Merck Sharp & Dohme LLCAbgeschlossen
-
CHU de ReimsAbgeschlossen
-
Tel-Aviv Sourasky Medical CenterUnbekanntWirksamkeit und Sicherheit des Hepatitis-B-Impfstoffs bei Patienten mit chronischer NierenerkrankungHepatitis B | Chronisches NierenleidenIsrael
-
Roswell Park Cancer InstituteZurückgezogenGesund, keine Anzeichen einer Krankheit
-
National Taiwan University HospitalNational Science Council, TaiwanAbgeschlossen